Society Logo
ME/CFS Australia Ltd
Please Click Here To Donate ME/CFS Australia (SA) Inc
 
Facebook
 
ME/CFS AUSTRALIA (SA) INC

Registered Charity 698

Email:
sacfs@sacfs.asn.au

Mailing address:
PO Box 28,
Hindmarsh,
South Australia 5007

Office:
266 Port Road,
Hindmarsh,
South Australia 5007
Ph: 1300 128 339

Office Hours:
Wednesdays, 10am-3pm


FIBROMYALGIA HELP:
Contact
Fibromyalgia SA
at the
Arthritis Foundation of SA
118 Richmond Road,
Marleston 5033
Ph: (08) 8379 5711

ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS Australia (SA) Inc aims to keep members informed of the various research projects, diets, medications, therapies etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
PDF Application Form 2014 (PDF, 290KB)
Why become a member?

Myalgic encephalomyelitis: International Consensus Criteria

Sunday 9 October 2011

From the Journal of Internal Medicine (via the Wiley Online Library):

 

Journal of Internal MedicineMyalgic encephalomyelitis: International Consensus Criteria

B. M. Carruthers1, M. I. van de Sande2, K. L. De Meirleir3, N. G. Klimas4, G. Broderick5, T. Mitchell6, D. Staines7,8, A. C. P. Powles9, N. Speight10, R. Vallings11, L. Bateman12,13, B. Baumgarten-Austrheim14, D. S. Bell15, N. Carlo-Stella16, J. Chia17,18, A. Darragh19, D. Jo20, D. Lewis21, A. R. Light22, S. Marshall-Gradisbik8, I. Mena23, J. A. Mikovits24, K. Miwa25, M. Murovska26, M. L. Pall27, S. Stevens28

Article first published online: 22 AUG 2011

DOI: 10.1111/j.1365-2796.2011.02428.x

© 2011 The Association for the Publication of the Journal of Internal Medicine

Keywords:
chronic fatigue syndrome; criteria; definition;
diagnosis; myalgic encephalomyelitis

Journal of Internal MedicineIssue
Journal of Internal Medicine
Volume 270, Issue 4,
pages 327–338,
October 2011

Abstract

The label ‘chronic fatigue syndrome’ (CFS) has persisted for many years because of the lack of knowledge of the aetiological agents and the disease process. In view of more recent research and clinical experience that strongly point to widespread inflammation and multisystemic neuropathology, it is more appropriate and correct to use the term ‘myalgic encephalomyelitis’ (ME) because it indicates an underlying pathophysiology. It is also consistent with the neurological classification of ME in the World Health Organization’s International Classification of Diseases (ICD G93.3).

Consequently, an International Consensus Panel consisting of clinicians, researchers, teaching faculty and an independent patient advocate was formed with the purpose of developing criteria based on current knowledge.

Thirteen countries and a wide range of specialties were represented. Collectively, members have approximately 400 years of both clinical and teaching experience, authored hundreds of peer-reviewed publications, diagnosed or treated approximately 50 000 patients with ME, and several members coauthored previous criteria. The expertise and experience of the panel members as well as PubMed and other medical sources were utilized in a progression of suggestions/drafts/reviews/revisions. The authors, free of any sponsoring organization, achieved 100% consensus through a Delphi-type process. The scope of this paper is limited to criteria of ME and their application. Accordingly, the criteria reflect the complex symptomatology.

Operational notes enhance clarity and specificity by providing guidance in the expression and interpretation of symptoms. Clinical and research application guidelines promote optimal recognition of ME by primary physicians and other healthcare providers, improve the consistency of diagnoses in adult and paediatric patients internationally and facilitate clearer identification of patients for research studies.

 

The full document can be found here.

 


 

blog comments powered by Disqus
Previous Previous Page